Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)

Ciaran Richardson, Sarah Gildea, Stephen Harkin, Annie Gallagher, Eimear Conroy, Lorraine McClafferty, Eibhlin McCole, El Ouard Benchikh, Cherith N. Reid, Marshall Dunlop, Sharon Savage, Philip Lowry, Jim Curry, Robert I. McConnell, John V. Lamont, Stephen P. FitzGerald
doi: https://doi.org/10.1101/2021.06.03.21255116

Data Availability

The data that support the findings of this study are available from the corresponding author, CR, upon reasonable request.

Back to top
Posted June 03, 2021.
Download PDF
Data/Code
Email
Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)
Ciaran Richardson, Sarah Gildea, Stephen Harkin, Annie Gallagher, Eimear Conroy, Lorraine McClafferty, Eibhlin McCole, El Ouard Benchikh, Cherith N. Reid, Marshall Dunlop, Sharon Savage, Philip Lowry, Jim Curry, Robert I. McConnell, John V. Lamont, Stephen P. FitzGerald
medRxiv 2021.06.03.21255116; doi: https://doi.org/10.1101/2021.06.03.21255116
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area